EIP Pharma has mapped out a financial freeway to the delivery of phase 2b on an ex-Vertex molecule. By merging with the floundering Diffusion Pharmaceuticals, the biotech is set to secure a Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results